Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset? Tempus AI Stock Slides Friday: Wha
Tempus AI (TEM) shares fell after Q2 results. The company reported revenue of $382.5 million, up 22% year over year, and a loss of 4 cents per share, better than the expected 14-cent loss. Revenue beat consensus ($379.7 million), but investors cited slower growth momentum and modest guidance. Stock was down 2.3% to $43.27.
How this was made
The 30-second read
Why it matters
Traders are likely repricing the back-half revenue trajectory and near-term momentum, using both earnings details and technical levels to frame risk.
Market read
This is a post-earnings technical and fundamental reset story: beat on revenue and narrower loss, but the market is emphasizing cooling growth and modest guidance uplift.
What to watch
The article does not quantify the guidance raise magnitude or back-half revenue drivers, so the market’s interpretation may be incomplete versus the company’s longer-cycle oncology data monetization.
Background
Tempus AI reported Q2 results after the prior close, then the stock sold off on investor focus shifting from the beat to growth durability and the size of the guidance raise.
Ticker impact
Tempus AI shares fell 2.30% after Q2 results, despite revenue and EPS loss beating expectations, with investors focused on cooling growth and modest guidance raise.
Near-term downside bias while price remains below the 50-day SMA and MACD stays below its signal line; watch $42.50 support and $51 resistance for confirmation.
The article cites a revenue beat but highlights cooling growth and modest guidance raise, plus a downtrend with price below key moving averages and negative MACD histogram, which together typically pressure rallies until technical levels are reclaimed.
Market effects
Signals that oncology data licensing and modeling growth durability is being questioned, which can affect sentiment toward precision-oncology data platforms.
None explicit beyond US small/mid-cap growth trading.
None explicit.
Counterpoint
A revenue beat with improving oncology volume and data licensing growth could still support longer-term positioning if investors are over-weighting near-term deceleration.
Key entities
- public_companyTempus AI
Subject of the article; stock is down after Q2 results and investors debate durability of growth and modest guidance raise.
